Recent Investment Analysts’ Ratings Updates for Integra LifeSciences (IART)

Integra LifeSciences (NASDAQ: IART) recently received a number of ratings updates from brokerages and research firms:

• 10/25/2025 – Integra LifeSciences had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.
• 10/15/2025 – Integra LifeSciences was given a new $15.00 price target on by analysts at Truist Financial Corporation. They now have a “hold” rating on the stock.
• 10/8/2025 – Integra LifeSciences had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.
• 10/7/2025 – Integra LifeSciences had its “sell” rating reaffirmed by analysts at Citigroup Inc.. They now have a $12.00 price target on the stock, up previously from $10.00.
• 9/27/2025 – Integra LifeSciences had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.